SPRC

+ Watchlist + Portfolio

SciSparc Ltd.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.55
52-Week Range: $2.98 – $43.74
Market Cap: $108.91M
P/E (TTM): 0.02
EPS (TTM): 248.24
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.41
PEG Ratio: —
Return on Equity: -315.62%
Return on Assets: -66.94%
Gross Margin: 73.95%
Operating Margin: -1720.78%
Profit Margin: 0.00%
Current Ratio: 0.87
Debt/Equity: 0.24
Total Debt: $2.68M
Free Cash Flow: $-6.78M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $8.18M

SPRC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.35M	$2.88M	$1.31M	$856.00K
Cost of Revenue	$322.00K	$683.00K	$800.00K	$225.00K
Gross Profit	$1.02M	$2.20M	$506.00K	$631.00K
Research & Development	$2.96M	$1.73M	$1.81M	$2.19M
Selling, General & Admin	$6.27M	$5.65M	$5.44M	$5.44M
Operating Expenses	$9.31M	$7.97M	$7.75M	$9.38M
Operating Income	-$8.29M	-$5.77M	-$7.24M	-$8.75M
EBITDA	-$2.35M	-$5.31M	-$6.97M	-$12.32M
Pretax Income	-$2.58M	-$5.86M	-$7.49M	-$12.56M
Income Tax	$14.00K	$22.00K	-$14.00K	$0.00
Net Income	-$2.59M	-$5.12M	-$6.28M	-$12.18M
Diluted EPS	-1874.19	2374.55	203.89	—
Diluted Shares	1383	2157	30820	—

SPRC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$3.57M	$2.08M	$1.54M	$4.59M
Receivables	$168.00K	$287.00K	$4.96M	$662.00K
Inventory	$668.00K	$742.00K	$113.00K	$75.00K
Current Assets	$4.51M	$6.45M	$7.50M	$5.44M
Total Assets	$10.61M	$11.18M	$10.35M	$7.62M
Current Liabilities	$4.16M	$1.57M	$1.40M	$2.25M
Total Debt	$27.00K	$76.00K	$46.00K	$366.00K
Total Liabilities	$4.16M	$1.59M	$1.41M	$2.48M
Retained Earnings	-$63.57M	-$68.69M	-$74.97M	-$87.15M
Shareholders' Equity	$6.45M	$7.61M	$8.15M	$4.24M
Working Capital	$354.00K	$4.87M	$6.10M	$3.18M

SPRC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$7.92M	-$5.89M	-$5.10M	-$4.14M
Capital Expenditure	-$4.87M	—	—	—
Free Cash Flow	-$12.79M	-$5.89M	-$5.10M	-$4.14M
Depreciation & Amortisation	$187.00K	$538.00K	$482.00K	$234.00K
Stock-Based Compensation	$897.00K	$196.00K	$569.00K	$1.19M
Investing Cash Flow	-$7.08M	-$4.09M	-$1.63M	-$1.40M
Financing Cash Flow	$11.70M	$8.48M	$6.19M	$8.59M
Dividends Paid	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$3.30M	-$1.50M	-$536.00K	$3.05M

SPRC Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q2 2025	Q4 2025
Cash & Equivalents	$1.54M	$1.54M	$4.59M
Receivables	$4.96M	$1.03M	$662.00K
Inventory	$113.00K	$154.00K	$75.00K
Current Assets	$7.50M	$2.75M	$5.44M
Total Assets	$10.35M	$5.14M	$7.62M
Current Liabilities	$1.40M	$5.04M	$2.25M
Total Debt	$46.00K	$2.11M	$366.00K
Total Liabilities	$1.41M	$5.22M	$2.48M
Retained Earnings	-$74.97M	-$84.30M	-$87.15M
Shareholders' Equity	$8.15M	-$782.00K	$4.24M
Working Capital	$6.10M	-$2.29M	$3.18M
Net Debt	—	$541.00K	—

Market Snapshot

About

SciSparc is a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. The company leverages a proprietary CBD-based drug platform to develop treatments for conditions including Tourette syndrome, Alzheimer disease, and autism spectrum disorder.